Genetic Analysis Market Report 2025

The genetic analysis market size has grown rapidly in recent years. It will grow from $9.09 billion in 2024 to $10.29 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to the increasing prevalence of genetic and rare diseases, expanding use of genetic testing in oncology, rising demand for personalized medicine, the need for early disease detection and prevention, and growing awareness of hereditary conditions.

The genetic analysis market size is expected to see rapid growth in the next few years. It will grow to $16.66 billion in 2029 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to the expansion of newborn screening programs, increasing application in the management of chronic conditions, a growing aging population, heightened focus on pediatric genetic testing, and rising incidence of lifestyle-related diseases with genetic components. Key trends in the forecast period include rapid advancements in next-generation sequencing technologies, the emergence of CRISPR and other gene-editing tools, enhanced bioinformatics and data interpretation platforms, adoption of AI and machine learning for genomic analysis, and the miniaturization of sequencing instruments.

The rising incidence of cancer is expected to drive the growth of the genetic analysis market in the coming years. Cancer occurs when certain cells in the body grow uncontrollably and may spread to other parts of the body. The prevalence of cancer is increasing due to an aging population, as older individuals are more likely to accumulate genetic mutations and experience prolonged exposure to environmental and lifestyle-related risk factors that contribute to cancer development. Genetic analysis is valuable in cancer care because it identifies specific genetic mutations responsible for the disease, enabling physicians to select targeted therapies that are more effective and have fewer side effects. For example, in May 2025, the National Cancer Institute (NCI), a US-based cancer research and training agency, reported that nearly 20 million people worldwide were newly diagnosed with cancer in 2022, and approximately 9.7 million died from the disease. Projections indicate that by 2050, new cancer cases could rise to 33 million annually, with deaths reaching 18.2 million. Consequently, the increasing prevalence of cancer is fueling the growth of the genetic analysis market.

Companies in the genetic analysis market are focusing on developing advanced solutions, such as genetic testing, to support preventive care and early monitoring. Genetic testing involves examining a person’s DNA to detect variations or mutations that may be linked to specific health conditions or inherited traits. For instance, in June 2023, Devyser, a Sweden-based company specializing in diagnostic kits, launched Devyser LynchFAP and Devyser BRCA PALB2, two genetic testing solutions for hereditary cancer. Devyser LynchFAP provides a comprehensive analysis of PMS2 and nine other genes associated with hereditary colorectal cancer, effectively addressing the challenge of distinguishing PMS2 from its pseudogene PMS2CL. It is the first commercial kit designed for precise PMS2 gene analysis. Devyser BRCA PALB2 enables targeted detection of variants in BRCA1, BRCA2, and PALB2, key genes associated with increased risk of breast and ovarian cancer. The solution is user-friendly, supports DNA analysis from both blood and tumor samples, and can be seamlessly integrated into laboratory workflows.

In February 2025, Tempus AI Inc., a US-based health technology company, acquired Ambry Genetics for an undisclosed amount. This acquisition enhances Tempus AI’s ability to leverage diagnostics and data to drive innovation, providing advanced solutions to clinicians, patients, and life sciences companies. Ambry Genetics is a US-based provider of genetic analysis solutions.

Major players in the genetic analysis market are Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Quest Diagnostics Inc., Illumina Inc., PerkinElmer Inc., BioRad Laboratories Inc., Qiagen NV, Oxford Nanopore Technologies Plc, 23andMe Inc., ELITech Group, MyHeritage Ltd., Dante Labs Inc., AutoGenomics Inc., IntegraGen SA, Family Tree DNA, 24 genetics, Centrillion Biosciences Inc., DNA Worldwide Group Ltd., and Genebase.

North America was the largest region in the genetic analysis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in genetic analysis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the genetic analysis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Genetic analysis is a scientific approach used to study deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and chromosomes in order to understand the structure, function, variation, and inheritance of genetic material. It focuses on the examination of genes and their interactions, allowing for the identification of genetic sequences and mutations. By analyzing genetic patterns and inheritance, this method provides valuable insights into biological functions and hereditary characteristics.

The primary outputs of genetic analysis include reagents and kits, instruments, and software. Reagents and kits consist of chemical substances and pre-prepared solutions used to perform specific biological reactions or procedures in laboratory experiments. Genetic analysis encompasses a variety of tests, including predictive genetic testing, carrier testing, prenatal and newborn testing, disease diagnostic testing, pharmacogenomic testing, and more, employing technologies such as next-generation sequencing (NGS), real-time PCR systems, and others. Its applications span cancer, genetic disorders, cardiovascular diseases, rare diseases, infectious diseases, and more, serving a range of end-users, including hospitals, research and development laboratories, diagnostic centers, and others.

The genetic analysis market research report is one of a series of new reports that provides genetic analysis market statistics, including genetic analysis industry global market size, regional shares, competitors with a genetic analysis market share, detailed genetic analysis market segments, market trends and opportunities, and any further data you may need to thrive in the genetic analysis industry. This genetic analysis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The genetic analysis market consists of revenues earned by entities by providing services such as bioinformatics analysis, transcriptome analysis, microarray analysis services, and custom assay development. The market value includes the value of related goods sold by the service provider or included within the service offering. The genetic analysis market also includes sales of genotyping arrays, library preparation kits, gene expression assays, and microarray slides. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.